What happened with XLO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Xilio Therapeutics is a clinical-stage biotechnology company developing drugs intended to activate the immune system against cancer. Its drugs carry a molecular mask designed to keep them inactive until enzymes within a tumor remove it. The aim is to activate treatment inside tumors rather than throughout the body; this approach remains unproven. Xilio has no approved products and earns no revenue from drug sales.
Its revenue comes from research collaborations and licenses with AbbVie and Gilead. These partners pay for access to Xilio’s programs through upfront payments and payments tied to development progress, with further payments and sales royalties possible if programs advance. Xilio performs early research for AbbVie, which takes responsibility for further development and commercialization of licensed programs. For Gilead, Xilio is testing efarindodekin alfa in patients with advanced solid tumors; Gilead can elect to take over development and commercialization after receiving an agreed clinical data package and paying a transition fee.
Xilio expects these two partners to supply nearly all its revenue for the foreseeable future. Further income depends on program progress and the partners’ decisions to continue development, while drug sales require regulatory approval. Xilio also relies on a single outside manufacturer, WuXi Biologics, for its drug candidates.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Gilead pays Xilio for rights to its masked IL-12 cancer program and development milestones, making it a direct source of Xilio funding. Watch whether Gilead elects to take over efarindodekin alfa after the Phase 2 data package, expected in the first half of 2027: that handover requires a $75 million transition payment.
AbbVie pays Xilio to discover cancer immunotherapies designed to stay inactive outside tumors and obtain licensing rights, then handles further development and commercialization of licensed products. Its decisions to license the T cell engager programs—treatments that bring T cells to cancer cells—and their development milestones are concrete signals to watch for further Xilio payments.
Werewolf Therapeutics challenges Xilio across IL-2, IL-12 and masked STEAP1 cancer programs; both develop treatments intended to activate inside tumors. Watch the efficacy and safety of Werewolf's WTX-124 and WTX-330, which offer competing approaches to stimulating antitumor immunity.
Janux Therapeutics competes with Xilio in masked treatments that bring T cells to PSMA-bearing cancer cells, known as T cell engagers. JANX007's Phase 1 results in adults with metastatic castration-resistant prostate cancer are the clearest clinical comparison to watch for Xilio's PSMA program.
CytomX Therapeutics competes with Xilio for cancer-treatment opportunities and drug-company partnerships by developing masked therapies intended to spare healthy tissue. Watch new PROBODY partnerships: they show which companies are backing CytomX's approach of using tumor enzymes to remove a protective mask and activate treatment.
Adagene's anti-CTLA-4 cancer antibodies compete with Xilio's vilastobart on improving efficacy and safety. Results from its lead candidate ADG126 are worth watching for whether it can reduce the toxicity that limits this treatment class, while Xilio seeks a partner for vilastobart.
Agenus's botensilimab competes with Xilio's vilastobart as a next-generation CTLA-4 cancer treatment, including in refractory colorectal cancer. Watch its botensilimab-plus-balstilimab results in that setting; revenue from authorized access programs does not mean the combination has marketing approval.
BioAtla competes with Xilio in tumor-selective cancer antibodies, including next-generation anti-CTLA-4 programs. Its antibodies are designed to bind targets under acidic tumor conditions rather than in normal tissue, offering a different route from Xilio's enzyme-activated masking to reducing harm to healthy tissue.
Xencor competes with Xilio's efarindodekin alfa through IL-12 oncology development, alongside broader competition in engineered antibody immunotherapies. Xencor also earns upfront payments, milestones and royalties by licensing candidates to partners for further development, so its IL-12 progress and licensing news are worth watching.
PDS Biotechnology competes with Xilio's efarindodekin alfa in developing IL-12 cancer treatments to stimulate antitumor immunity. Watch its IL-12 development progress rather than product sales: through the period covered by its 2025 annual filing, PDS had no product revenue and funded operations mainly through stock issuance and debt.
Gilead Sciences Inc earningsGILD
Gilead’s report matters because progress on its IL-12 program could bring a conditional $75 million transition payment to Xilio if Gilead takes over the licensed program.
Watch for updates on Gilead’s development plans for efarindodekin alfa and any indication it may take over the program. If Gilead ultimately does so, the agreement calls for a $75 million transition payment to Xilio; without that decision, the payment remains conditional, not assured revenue. The takeaway is whether this partnership has shown concrete progress toward a potential source of funding.
Xilio Therapeutics, Inc. earningsThis company
Xilio Therapeutics has no product sales and relies on collaboration payments to fund research, so this report shows how partner revenue and cash use shape its funding runway.
Read collaboration and license revenue alongside cash used in operations. Higher revenue with contained cash use would show partner payments helping Xilio fund development for longer; lower revenue or faster cash use would leave it more reliant on future milestones or outside financing. Collaboration revenue can vary with milestones and accounting timing, so it is not product sales or necessarily steady cash flow. The question is whether Xilio’s funding buffer is widening or narrowing.
